172 related articles for article (PubMed ID: 32047232)
21. Clinical application of RNA sequencing in sarcoma diagnosis: An institutional experience.
Pei J; Zhao X; Patchefsky AS; Flieder DB; Talarchek JN; Testa JR; Wei S
Medicine (Baltimore); 2019 Jun; 98(25):e16031. PubMed ID: 31232935
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of molecular inversion probe versus TruSeq® custom methods for targeted next-generation sequencing.
Almomani R; Marchi M; Sopacua M; Lindsey P; Salvi E; Koning B; Santoro S; Magri S; Smeets HJM; Martinelli Boneschi F; Malik RR; Ziegler D; Hoeijmakers JGJ; Bönhof G; Dib-Hajj S; Waxman SG; Merkies ISJ; Lauria G; Faber CG; Gerrits MM;
PLoS One; 2020; 15(9):e0238467. PubMed ID: 32877464
[TBL] [Abstract][Full Text] [Related]
23. Fluorescence in situ analysis of soft tissue tumor associated genetic alterations in formalin-fixed paraffin-embedded tissue.
Horn H; Allmanritter J; Doglioni C; Marx A; Müller J; Gattenlöhner S; Staiger AM; Rosenwald A; Ott G; Ott MM
Pathol Res Pract; 2014 Dec; 210(12):804-11. PubMed ID: 25446247
[TBL] [Abstract][Full Text] [Related]
24. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
25. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
[TBL] [Abstract][Full Text] [Related]
26. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.
Zacher A; Kaulich K; Stepanow S; Wolter M; Köhrer K; Felsberg J; Malzkorn B; Reifenberger G
Brain Pathol; 2017 Mar; 27(2):146-159. PubMed ID: 26919320
[TBL] [Abstract][Full Text] [Related]
27. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
28. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
29. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
[TBL] [Abstract][Full Text] [Related]
30. Pre-clinical validation of a next generation sequencing testing panel.
Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
[TBL] [Abstract][Full Text] [Related]
31. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience.
Hindi I; Shen G; Tan Q; Cotzia P; Snuderl M; Feng X; Jour G
Exp Mol Pathol; 2020 Jun; 114():104403. PubMed ID: 32061944
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.
Letovanec I; Finn S; Zygoura P; Smyth P; Soltermann A; Bubendorf L; Speel EJ; Marchetti A; Nonaka D; Monkhorst K; Hager H; Martorell M; Sejda A; Cheney R; Hernandez-Losa J; Verbeken E; Weder W; Savic S; Di Lorito A; Navarro A; Felip E; Warth A; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dienemann H; Dziadziuszko R; Vansteenkiste J; O'Brien C; Geiger T; Sherlock J; Schageman J; Dafni U; Kammler R; Kerr K; Thunnissen E; Stahel R; Peters S;
J Thorac Oncol; 2018 Mar; 13(3):413-425. PubMed ID: 29191776
[TBL] [Abstract][Full Text] [Related]
34. Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and rt-PCR.
Jin L; Majerus J; Oliveira A; Inwards CY; Nascimento AG; Burgart LJ; Lloyd RV
Diagn Mol Pathol; 2003 Dec; 12(4):224-30. PubMed ID: 14639108
[TBL] [Abstract][Full Text] [Related]
35. The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities.
Noujaim J; Jones RL; Swansbury J; Gonzalez D; Benson C; Judson I; Fisher C; Thway K
Br J Cancer; 2017 Feb; 116(5):669-678. PubMed ID: 28141799
[TBL] [Abstract][Full Text] [Related]
36. A Novel Next-Generation Sequencing-Based Approach for Concurrent Detection of Mitochondrial DNA Copy Number and Mutation.
Zhou K; Mo Q; Guo S; Liu Y; Yin C; Ji X; Guo X; Xing J
J Mol Diagn; 2020 Dec; 22(12):1408-1418. PubMed ID: 33011442
[TBL] [Abstract][Full Text] [Related]
37. Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing.
Janaki N; Harbhajanka A; Michael CW; Bomeisl P; Wasman J; Atchley M; Miskiewicz K; Alouani D; Sadri N
Cancer Cytopathol; 2019 May; 127(5):297-305. PubMed ID: 30933438
[TBL] [Abstract][Full Text] [Related]
38. Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing: A Solution for Transferring Integrated Pangenomic Studies into Routine Practice?
Garinet S; Néou M; de La Villéon B; Faillot S; Sakat J; Da Fonseca JP; Jouinot A; Le Tourneau C; Kamal M; Luscap-Rondof W; Boeva V; Gaujoux S; Vidaud M; Pasmant E; Letourneur F; Bertherat J; Assié G
J Mol Diagn; 2017 Sep; 19(5):776-787. PubMed ID: 28826610
[TBL] [Abstract][Full Text] [Related]
39. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
40. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
